%PDF-1.4
%
42 0 obj
<>
endobj
44 0 obj
<>stream
2005-10-07T13:22:35Z
QuarkXPress(tm) 6.5
2024-03-28T18:43:01-07:00
2024-03-28T18:43:01-07:00
QuarkXPress(tm) 6.5
%%DocumentProcessColors: Black
%%EndComments
uuid:26f79f70-1dd2-11b2-0a00-cb08275dc400
uuid:26f79f73-1dd2-11b2-0a00-810000000000
application/pdf
endstream
endobj
10 0 obj
<>]>>
endobj
35 0 obj
<>
endobj
36 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
37 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
38 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
39 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
40 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
41 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
71 0 obj
[76 0 R]
endobj
72 0 obj
<>stream
1 g
/GS0 gs
0 783 0 0 re
f
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 47.5 731.694 Tm
[(2.)-875 (Gridley G, McLaughlin JK, Ekbom )55 (A, et al. Incidence of cancer)]TJ
1.675 -1.25 Td
(among patients with rheumatoid arthritis. J Natl Cancer Inst)Tj
0 Tw 0 -1.25 TD
[(1993;85:307-1)37 (1.)]TJ
0.02499 Tw -1.675 -1.25 Td
[(3.)-875 (Mellemkj\276r L, Linet MS, Gridley G, Frisch M, M\277ller H, Olsen)]TJ
1.675 -1.25 Td
(JH. Rheumatoid arthritis and cancer risk. Eur J Cancer)Tj
0 Tw T*
(1996;32A:1753-7.)Tj
0.02499 Tw -1.675 -1.25 Td
[(4.)-875 (Isomaki HA, Hakulinen )18 (T)74 (, Ekbom )55 (A, et al. Excess risk of )]TJ
1.675 -1.25 Td
(lymphomas, leukemia, and myeloma in patients with rheumatoid)Tj
T*
(arthritis. J Chronic Dis 1978;31:691-6.)Tj
-1.675 -1.25 Td
[(5.)-875 (Baecklund E, Ekbom )56 (A, Spar\216n P)110 (, Feltelius N, Klareskog L.)]TJ
1.675 -1.25 Td
(Disease activity and risk of lymphoma in patients with rheumatoid)Tj
T*
[(arthritis: nested case-control study)66 (. BMJ 1998;317:180-1.)]TJ
-1.675 -1.25 Td
[(6.)-875 (W)80 (olfe F)80 (, Michaud K. L)55 (ymphoma in rheumatoid arthritis. )19 (The ef)18 (fect)]TJ
1.675 -1.25 Td
(of methotrexate and anti-tumor necrosis factor therapy in 18,572)Tj
T*
[(patients. )55 (Arthritis Rheum 2004;50:1740-51.)]TJ
-1.675 -1.25 Td
[(7.)-875 (Efird JT)74 (, Friedman GD, Habel L, )18 (T)70 (ekawa IS, Nelson LM. Risk of)]TJ
1.675 -1.25 Td
(subsequent cancer following invasive or in situ squamous cell skin)Tj
T*
[(cancer)55 (. )55 (Ann Epidemiol 2002;12:469-75.)]TJ
-1.675 -1.25 Td
[(8.)-875 (Friedman GD, )18 (T)70 (ekawa IS. )54 (Association of basal cell skin cancers)]TJ
1.675 -1.25 Td
(with other cancers \(United States\). Cancer Causes Control)Tj
T*
(2)Tj
0 Tw [(000;1)37 (1:891-7.)]TJ
0.02499 Tw -1.675 -1.25001 Td
[(9.)-875 (Miller DL, )18 (W)80 (einstock MA. Nonmelanoma skin cancer in the United)]TJ
1.675 -1.25 Td
[(States: Incidence. J )56 (Am )54 (Acad Dermatol 1994;30:774-8.)]TJ
-2.175 -1.25 Td
[(10.)-875 (Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl )]TJ
-0.00011 Tc 2.175 -1.25 Td
(J)Tj
0 Tc 0.6639 0 Td
(Med 1992;327:1649-62.)Tj
-2.80204 -1.25 Td
[(1)36.9 (1.)-875 (De Hertog SAE, )17 (W)80 (ensveen )55 (AH, Bastiaens MT)74 (, et al. Relation)]TJ
2.13814 -1.25 Td
[(between smoking and skin cancer)56 (. J Clin Oncol 2001;19:231-8.)]TJ
-2.175 -1.25 Td
[(12.)-875 (Kwa RE, Campana K, Moy RL. Biology of cutaneous squamous)]TJ
2.175 -1.25 Td
[(cell carcinoma. J )56 (Am )55 (Acad Dermatol 1992;26:1-26.)]TJ
0 Tw -2.175 -1.25 Td
(13.)Tj
0.02499 Tw 2.125 0 Td
(Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other )Tj
0.05 -1.25 Td
[(disorders after immunosuppressive treatment. )56 (Am J Med 1985;78)]TJ
T*
(Suppl 1A:44-9.)Tj
-2.175 -1.25 Td
[(14.)-875 (Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell)]TJ
2.175 -1.25 Td
(carcinoma in patients with rheumatoid arthritis after starting tumor)Tj
T*
(necrosis factor a receptor IgG1-Fx fusion complex therapy)Tj
-0.00011 Tc 23.57051 0 Td
[(.)-274.9 (J)]TJ
0 Tc 0 Tw 1.13399 0 Td
(Am)Tj
0.02499 Tw -24.7045 -1.25001 Td
(Acad Dermatol 2001;45:953-6.)Tj
30.825 43.75 Td
[(15.)-875 (Esser )55 (AC, )54 (Abril )55 (A, Fayne S, Doyle JA. )54 (Acute development of )]TJ
2.175 -1.25 Td
(multiple keratoacanthomas and squamous cell carcinomas after)Tj
T*
[(treatment with infliximab. J )57 (Am )54 (Acad Dermatol 2004;50 Suppl)]TJ
0 Tw T*
(5:S75-7.)Tj
0.02499 Tw -2.175 -1.25 Td
[(16.)-875 (Lebwohl M, Kim D, Do )17 (T)74 (, et al. Cutaneous squamous cell )]TJ
2.175 -1.25 Td
(carcinoma incidence is not increased in rheumatoid arthritis)Tj
T*
(patients receiving Etanercept [abstract]. EULAR 2003;THU0247.)Tj
-0.03 Tw T*
[([Internet.] Accessed August )-55 (4, )-55 (2005. A)74 (vailable )-55 (from:)]TJ
0 Tw T*
[(http://www)65 (.eular)55 (.or)18 (g)]TJ
0.02499 Tw -2.175 -1.25 Td
[(17.)-875 (Bur)18 (ge D. Etanercept and squamous cell carcinoma. J )56 (Am )55 (Acad)]TJ
2.175 -1.25 Td
(Dermatol 2003:49:358-9.)Tj
-2.175 -1.25 Td
[(18.)-875 (W)80 (olfe F)80 (, Flowers N, )54 (Anderson J. )17 (The National Rheumatic Disease)]TJ
2.175 -1.25 Td
(Data Bank: case mix and severity characteristics of patients in)Tj
T*
[(rheumatological practice [abstract]. )57 (Arthritis Rheum 1998;41)]TJ
0 Tw T*
(Suppl:S132.)Tj
0.02499 Tw -2.175 -1.25 Td
[(19.)-875 (W)80 (olfe F)80 (, Michaud K. Heart failure in rheumatoid arthritis: rates,)]TJ
2.175 -1.25 Td
[(predictors, and the ef)19 (fect of anti-)-1 (t)1 (u)-1 (mor nec)1 (ro)-1 (s)1 (is factor therapy)66 (. )55 (Am)]TJ
-0.00011 Tc T*
(J)Tj
0 Tc 0.66387 0 Td
[(Med 2004;1)37 (16:305-1)36 (1.)]TJ
-2.83887 -1.25 Td
[(20.)-875 (Fries JF)79 (, Spitz P)111 (, Kraines RG, Holman HR. Measurement of patient)]TJ
2.175 -1.25 Td
[(outcome in arthritis. )56 (Arthritis Rheum 1980;23:137-45.)]TJ
-2.175 -1.25 Td
[(21.)-875 (Oliveria SA, Christos PJ, Halpern )55 (AC, Fine JA, Barnhill RL,)]TJ
2.175 -1.25001 Td
(Berwick M. Evaluation of factors associated with )Tj
T*
(skin self-examination. Cancer Epidemiol Biomarkers Prev)Tj
0 Tw T*
(1999;8:971-8.)Tj
0.02499 Tw -2.175 -1.25 Td
[(22.)-875 (Euvard S, Kanitakis J, Claudy )55 (A. Skin cancers after or)18 (gan)]TJ
2.175 -1.25 Td
(transplantation. N Engl J Med 2003;348:1681-91.)Tj
-2.175 -1.25 Td
[(23.)-875 (Caforio )55 (ALP)110 (, Fortina )55 (AB, Piaserico S, et al. Skin cancer in heart)]TJ
2.175 -1.25 Td
(transplant recipients. Risk factor analysis and relevance of )Tj
T*
[(immunosuppressive therapy)65 (. Circulation 2000;102 Suppl III:222-7.)]TJ
ET
0 0 0 1 K
39.968 72 m
544.968 72 l
S
0 0 0 0 k
480.79 49.2 64.178 15.665 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tw 8 0 0 8 527.968 51.9343 Tm
(2135)Tj
ET
0 0 0 0 k
40.032 50.335 203 15.6649 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 41.032 53.0695 Tm
[(Chakravarty)55 (, et al: Skin cancer and RA)]TJ
ET
0 0 0 0 k
/GS2 gs
90.282 66.25 407.5 10.833 re
f
BT
0 0 0 1 k
/GS1 gs
/T1_2 1 Tf
0.033 Tc 0.028 Tw 8 0 0 8 96.3264 69.6274 Tm
[(Personal non-commercial use only)71 (. )18 (The Journal of Rheumatology Copyright )-3 (\251)-339 (2005. )54 (All rights reserved.)]TJ
ET
0.5 w
90.282 66.25 407.5 10.833 re
h
S
BT
0 g
/GS3 gs
/T1_3 1 Tf
0 Tc 0 Tw 10 0 0 10 513 8 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
26 0 obj
<>
endobj
14 0 obj
<>
endobj
18 0 obj
<>
endobj
50 0 obj
<>
endobj
15 0 obj
<>
endobj
17 0 obj
<>
endobj
16 0 obj
<>stream
KDTIMW+Helvetica F #!
?
? V_5.0d8e2 1990-99 Apple Computer Inc. 1981 Linotype AG 1990-91 Type Solutions Inc.Helvetica 1 F S T P O B M D N J V Z 5 I + G 3 U H $ Q " W E ! " j Y"$3g3r4u
u
35rCjL`CC[b ZyC.):TIG ǁvdB }ag`¼ܞίE~\takgSM@l-]/#m ڀsg@1,nL9`4\M=H,IRd#
CoM?
Ai 8#4ShE_4Wdp]ts\jfb>v^D 51_5HZort#gxz|sh]
R<^r|}m+?xUpZ(L:'qBlnYzNk8mO}H ߋjHcVJ7KC |nV$,X&,?}Чª̔Γמ%Y<'ZnPM|L#3H g]r [I[9'`jt_uɋÛtw{Zd=<%mS2<Τ7Wmt{}noybWCHH:+MM
_pHz<C3j5*)W4:k<)Cl3H־rYjVBOKq
!_#|O]}oW)$ U;spnWF6@GwPbhsee`V,FWKK'`K`K}Ll0BT%X-ާ2>H"9rO^5S4Okz[
` x[TkvrrHvvL8dd*L0[:CnneneXC^C}>H%)nPfR<7MC|mT!/4CxeQiuee`UH
JYg7w^BjFg!+F4O"G$pSН:E<)")0F0H"F|8lut:lNath~U@`zweD"WLO'5C[
YǂyjK+rrlvÄY?SD=FB/<:<Z%'%Y,<"pxzjt}r~O?'?J}]h_,|;'$rR`*1Z4KbqzKpA'{c!%ڟb:hhiLB73|>nI V0Q9!ޤ=n?@+REmg-$#W?Z1 /Vw*m=bP>S'Ӌ58W\QVte|}
6\rߤP
NA6!<fE+HZiwhy܋;}UU9DwNc`pdfgZ"C
n?P?/!K˙ǧѶ6'
U(RJDw.MG?pCHC(M)CDN*
(MCC(
N*DC)(Bs
_C@####B__BD####C@__B#$$#BC__B$##$B_}k>ҵŰ̯
źܳm%h܋YF=_